Molecular Partners AG
🇬🇧XLON.0QXXUnited KingdomNot reported
Price£3.39+0.07 (+2.11%)
Latest anomalies
Neutral 0 detected in the last 120 days
- High: 6
- Medium: 0
- Low: 0
EBITDA margin: collapsed against the prior period
EBIT margin: collapsed against the prior period
Free cash flow margin: collapsed against the prior period
Gross margin: collapsed against the prior period
Net margin: collapsed against the prior period
Free with a Finzer account.
Profile
- United Kingdom
Identity
- Exchange
- London Stock Exchange . XLON
- Type
- Stock
- ISIN
- Not reported
- CUSIP
- Not reported
Company
- Employees
- 158
- Headquarters
- Schlieren, Germany
Market
- Shares outstanding
- 21.2M
- Market cap
- £115.86M
Highlights
No high and low reported for today's session.
- Market cap
- £115.86M
- EPS LTM
- -CHF 1.73
- P/E LTM
- -2.13
- Div yield
- Not reported
Fundamentals (LTM)
- Revenue
- CHF 681K-91.34%down year on year
- Net income
- -CHF 64.81M-12.46%down year on year
- Gross margin
- -62.26%+88.58%up year on year
- Free cash flow
- -CHF 57.6M+2.65%up year on year
Latest news
News is not sourced for this exchange.
Business summary
Molecular Partners AG is listed on London Stock Exchange (United Kingdom) under the ticker 0QXX. Its market capitalisation is £115.86M, from 21.2M shares outstanding, as of . Across the 174 trading sessions to the shares traded between £2.72 and £3.94, and the last close of £3.39 sits 55% of the way up that range. The company is headquartered in Schlieren, Germany, and employs about 158 people. This is the London Stock Exchange listing of Molecular Partners AG; its primary listing is MOLN on SIX Swiss Exchange.
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in preclinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and Radio-DARPin Therapy to treat ovarian disease. In addition, the company develops MP0621, a molecular partners' first Switch-DARPin program, which is in preclinical trial designed to induce killing of hematopoietic stem cells (HSCs) as a next-generation conditioning regimen for HSC transplantation (HSCT); and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.